Feb. 27, 2013
/PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host "
Treatment of Pain and Opioid Dependence with Buprenorphine"
for investors and analysts on
Thursday, March 7, 2013
, in New York City. This event will include
insightful discussion from medical experts with extensive experience in the management of chronic pain and opioid dependence using various formulations of buprenorphine, including BDSI's BEMA Buprenorphine and BEMA Buprenorphine/Naloxone (BNX).
The presentations from physician experts include:
- "Treatment of Chronic Pain with Buprenorphine" by Joseph Pergolizzi, M.D. – Adjunct Assistant Professor at Johns Hopkins University School of Medicine and a senior partner in the Naples Anesthesia and Pain Associates Group. He is also the co-founder and chairman for the Association of Chronic Pain Patients.
- " Treatment of Opioid Dependence with Buprenorphine" by Gregory Sullivan, M.D. –Board certified in Addiction Medicine and Medical Director of Parkway Medical Center in Birmingham, Alabama. For twenty years, Dr. Sullivan has been actively involved in government and pharmaceutical research on the mechanism, biology and treatment of addiction and pain.
- Panel discussion featuring Genie Bailey, MD, who will address topics including patient perspectives on the treatment of opioid dependence. Dr. Bailey is Assistant Clinical Professor of Psychiatry and Human Behavior at The Warren Alpert Medical School of Brown University and Director of Research and Medical Director of the Dual Diagnosis Unit at Stanley Street Treatment and Resources, Inc (SSTAR).
All three experts will be on the panel and have participated in either the BEMA Buprenorphine chronic pain or BNX opioid addiction programs and will be able to offer their perspectives based on "hands on" experiences.